63 patents
Utility
Preparation of factor Xa derivatives
19 Dec 23
The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product.
Mark Karbarz, Pamela B. Conley, Genmin Lu
Filed: 9 Mar 21
Utility
Antidotes for factor Xa inhibitors and methods of using the same
12 Dec 23
The present invention relates antidotes to anticoagulants targeting factor Xa.
Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
Filed: 7 May 20
Utility
Method of quantitating unbound C5a in a sample
28 Nov 23
A method of quantitating free (unbound) human C5a complement protein (C5a) from a sample comprising: binding biotinylated anti-C5a capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5a; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument; wherein human C5 is first removed from the sample.
Mark Dysinger, Mark Ma
Filed: 19 Oct 17
Utility
Methods and compositions for treating complement-associated disorders
7 Nov 23
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders.
Russell P. Rother
Filed: 20 Mar 19
Utility
Humanized anti-CD200 antibodies and uses thereof
31 Oct 23
Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200.
Taneisha Ann-Tanara Mack, Douglas L. Sheridan, Tadas Panavas
Filed: 20 Dec 18
Utility
Biomarker signature for predicting tumor response to anti-CD200 therapy
19 Sep 23
Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor.
Rui-Ru Ji, Mark Hamilton, Sharon Barr
Filed: 26 Sep 18
Utility
Solid forms of Cerdulatinib
1 Aug 23
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state.
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Filed: 16 Nov 20
Utility
Solid forms of Cerdulatinib
30 May 23
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state.
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Filed: 16 Nov 20
Utility
Antibody immune cell inhibitor fusion proteins
9 May 23
The disclosure provides antibody immune cell inhibitor fusion proteins comprising four polypeptide chains that form two antigen binding sites and at least two immune cell receptor binding sites that inhibit or diminish activation of an immune effector cell when bound to a target antigen.
Julian Chandler
Filed: 23 Apr 18
Utility
Methods of treating a subject with an alkaline phosphatase deficiency
31 Jan 23
Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional analytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional analytes.
Tatjana Odrljin
Filed: 19 Feb 20
Utility
Lysosomal storage disease enzymes
24 Jan 23
The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
Anthony Quinn, Alex J. Harvey
Filed: 9 Nov 20
Utility
Bis-choline tetrathiomolybdate for treating Wilson disease
29 Nov 22
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
Filed: 4 Dec 18
Utility
Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
15 Nov 22
The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin.
Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini
Filed: 11 Jul 18
Utility
Dosage and administration of anti-C5 antibodies for treatment of protein-losing enteropathy in patients
4 Oct 22
Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).
Orly Eshach Adiv, Camille Bedrosian, Hagit Baris Feldman, Alina Kurolap, Susan Faas McKnight
Filed: 21 May 18
Utility
Cerdulatinib for treating hematological cancers
20 Sep 22
Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.
Gregory Coffey, Jiajia Feng, Andrew Steele
Filed: 16 Jul 20
Utility
Anti-C5 antibodies having improved pharmacokinetics
6 Sep 22
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders.
Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
Filed: 23 Jan 20
Utility
Bis-choline tetrathiomolybdate for treating Wilson Disease
23 Aug 22
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
Filed: 19 Aug 20
Utility
Inhibitors of protein kinases
16 Aug 22
Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
Filed: 26 Nov 19
Utility
Anti-C5A antibodies
9 Aug 22
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
Filed: 12 Sep 19
Utility
Methods for treating craniosynostosis in a patient
2 Aug 22
The disclosure features methods for treating craniosynostosis in a patient (e.g., a patient having hypophosphatasia (HPP) and exhibiting or likely to have increased intracranial pressure (ICP)) by administering a soluble alkaline phosphatase (sALP) to the patient, e.g., in combination with a cranial surgery, e.g., a cranial vault remodeling procedure.
Howard M. Saal, Timothy W. Vogel
Filed: 30 Oct 15